Case Report
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jul 24, 2020; 11(7): 504-509
Published online Jul 24, 2020. doi: 10.5306/wjco.v11.i7.504
Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report
Yuri Ozaki, Akiyo Yoshimura, Masataka Sawaki, Masaya Hattori, Naomi Gondo, Haruru Kotani, Yayoi Adachi, Ayumi Kataoka, Kayoko Sugino, Nanae Horisawa, Yuka Endo, Kazuki Nozawa, Shoko Sakamoto, Hiroji Iwata
Yuri Ozaki, Akiyo Yoshimura, Masataka Sawaki, Masaya Hattori, Naomi Gondo, Haruru Kotani, Yayoi Adachi, Ayumi Kataoka, Kayoko Sugino, Nanae Horisawa, Yuka Endo, Kazuki Nozawa, Shoko Sakamoto, Hiroji Iwata, Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan
Author contributions: Ozaki Y contributed to study conception, data collection, and manuscript writing; Yoshimura A and Iwata H supervised the study and revised the manuscript before submission; all authors read and approved the final manuscript.
Informed consent statement: Written informed consent was obtained from the patient for the publication of personal details and accompanying images in this manuscript.
Conflict-of-interest statement: The authors declare that they have no competing interests in relation to the present work.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Yuri Ozaki, MD, Surgical Oncologist, Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1 kanoko-den chikusa-ku Nagoya City, Aichi, Nagoya 464-8681, Japan. yozaki@aichi-cc.jp
Received: February 14, 2020
Peer-review started: February 14, 2020
First decision: May 28, 2020
Revised: June 2, 2020
Accepted: June 10, 2020
Article in press: June 10, 2020
Published online: July 24, 2020
Core Tip

Core tip: Combination therapy with Bevacizumab and chemotherapy is used to expect its high antitumor effect. However, Bevacizumab-containing combination therapies can induce severe adverse events. Mechanisms and risk factors that underlie the onset of pneumothorax are not clear. Here, we report a case of pneumothorax associated with a combination therapy of Bevacizumab with chemotherapy, and discuss the mechanisms and risk factors. Patients with multiple lung metastases surrounding the bronchi and on the pleura, should be monitored for pneumothorax, an adverse event that can be induced by the rapid necrosis due to Bevacizumab-containing combination chemotherapies.